|

Liver Damage and Cardiometabolic Disorders in NAFLD

RECRUITINGSponsored by University of Roma La Sapienza
Actively Recruiting
SponsorUniversity of Roma La Sapienza
Started2011-11
Est. completion2036-12-31
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04036357

Summary

Liver fibrosis is the most important prognostic factor in patients with non-alcoholic factor disease. Clinical and biological condition, as diabetes or mutation for PNPLA3, are well known factors associated with liver fibrosis onset and progression. However, little is known about biochemical factors predicting liver fibrosis evolution in large NAFLD populations.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients aged 18 years old or more
* Patients with at least on of the following metabolic disorders

  * Obesity
  * Diabetes
  * Arterial hypertension
  * Dyslipidemia

Exclusion Criteria:

* Average daily consumption of alcohol \>20 g in women and of \>30 g in men (assessed by Alcohol Use Disorders Identification Test, AUDIT;
* presence of hepatitis B surface antigen and antibody to hepatitis C virus;
* positive tests for autoimmune hepatitis;
* cirrhosis and other chronic liver diseases;
* diagnosis of oncological diseases
* concomitant therapy with drugs known to promote liver steatosis (e.g. amiodarone);
* other chronic infectious or autoimmune disease;

Conditions5

Cardiovascular DiseasesCardiovascular Risk FactorLiver DiseaseLiver FibrosesNAFLD

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.